# US 9,040,553 B2 · Phenoxyisobutyric acid compounds and method of synthesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,040,553 B2
- Document ID: US9040553B2
- Status: Granted
- Kind: B2
- Application number: 13/940,008
- Filed: 2013-07-11
- Published: 2014-11-27
- Granted: 2015-05-26
- Earliest claimed: 2010-09-17
- Assignees: Cell Viable Corporation
- Applicants: Iraj Lalezari; Jill Fabricant
- Inventors: Iraj Lalezari; Jill Fabricant
- Web page: https://patentgrep.com/patent/US9040553B2

## CPC

- C07D 307/87: Benzo [c] furans; Hydrogenated benzo [c] furans
- A61K 8/411: {Aromatic amines, i.e. where the amino group is directly linked to the aromatic nucleus}
- A61K 8/42: Amides
- A61K 8/4926: {having six membered rings}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61Q 19/08: Anti-ageing preparations
- C07C 215/76: of the same non-condensed six-membered aromatic ring
- C07C 229/40: having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C 233/75: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C 235/72: with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C 235/74: of a saturated carbon skeleton
- C07C 275/34: having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C 275/42: being further substituted by carboxyl groups
- C07D 215/12: with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D 215/14: Radicals substituted by oxygen atoms
- C07D 215/50: attached in position 4
- C07D 215/52: with aryl radicals attached in position 2
- C07D 219/04: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).

## Claims

### Claim 1

A compound of the formula:

### Claim 2 (depends on 1)

A pharmaceutical composition which comprises a compound as defined in claim 1 and a pharmaceutically acceptable diluent.

### Claim 3 (depends on 1)

A pharmaceutically acceptable salt of a compound of claim 1 and a pharmaceutical carrier.

### Claim 4 (depends on 1)

A method of treating Type I diabetes which comprises administering to a Type I diabetic patient an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound.

### Claim 5 (depends on 1)

A method of treating Type II diabetes which comprises administering to a Type II diabetic patient an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound.